Physician profile
Sarah W W Sherman
NPI 1255587671
$41,063.01
in general payments reported to CMS, 2019-2025
23 companies · $19K in 2025
The $19K reported for 2025 was more than what 99% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,819 · 2022: $4,661 · 2023: $1,595 · 2024: $13K · 2025: $19K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $26K · Food and Beverage: $4,224 · Travel and Lodging: $2,648 · Consulting Fee: $1,000 · Education: $49.68.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $25,660.86 |
| Food and Beverage | $4,223.62 |
| Travel and Lodging | $2,648.06 |
| Consulting Fee | $1,000.00 |
| Education | $49.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $26,116.73 | 2021-2025 | Tremfya, Stelara |
| Abbvie INC. | $12,940.12 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $383.73 | 2021-2025 | Entyvio, Eohilia, Gattex |
| Genzyme Corporation | $316.62 | 2023-2025 | |
| Ardelyx, INC. | $238.22 | 2022-2025 | Ibsrela |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $197.49 | 2021-2024 | Xifaxan, Trulance |
| Janssen Scientific Affairs, LLC | $136.82 | 2022-2025 | Tremfya |
| Nestle Healthcare Nutrition INC. | $82.42 | 2021-2023 | |
| Qol Medical, LLC | $81.66 | 2024-2025 | Sucraid, Sucraid |
| Merck Sharp & Dohme LLC | $81.59 | 2021-2024 | Dificid |
| Celgene Corporation | $68.05 | 2021-2023 | Zeposia |
| Phathom Pharmaceuticals, INC. | $61.83 | 2024-2025 | Voquezna |
| Organon LLC | $57.21 | 2024-2025 | Hadlima, Renflexis |
| Lilly USA, LLC | $48.53 | 2025 | Omvoh |
| Celltrion USA INC. | $40.03 | 2024 | Zymfentra |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $35.36 | 2023-2024 | Rebyota |
| Mallinckrodt Hospital Products INC. | $35.26 | 2025 | Terlivaz |
| Vivus LLC | $29.02 | 2021-2024 | Qsymia |
| Ultragenyx Pharmaceutical INC. | $27.23 | 2022 | |
| Ironwood Pharmaceuticals, INC | $23.82 | 2023 | Linzess |
| Ipsen Biopharmaceuticals, INC | $23.36 | 2025 | Iqirvo |
| Braintree Laboratories, INC. | $21.40 | 2024 | Sutab, Suflave |
| Pfizer INC. | $16.51 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah W Sherman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.